Clinical Trial Update: Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) [Phase 3]

View source ↗

Summary

Phase 3 trial of elafibranor vs placebo in nonalcoholic steatohepatitis with fibrosis was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis with Fibrosis

Drugs mentioned

• Elafibranor

Snippet

Sponsor: Genfit | Conditions: Nonalcoholic Steatohepatitis (NASH) With Fibrosis | Phase 3 | Status: TERMINATED | Results posted: 2022-03-23